Neurophysiological studies provide objective measures of brain dysfunction in Progressive Supranuclear Palsy (PSP), offering insights into subclinical abnormalities that may precede overt clinical symptoms. Electrophysiology complements neuroimaging and fluid biomarkers by directly assessing neuronal and network function. Key modalities include electroencephalography (EEG), event-related potentials (ERP), transcranial magnetic stimulation (TMS), and multimodal evoked potentials. These techniques reveal cortical hyperexcitability, sensory processing deficits, and brainstem involvement that characterize PSP pathophysiology.
Quantitative EEG analysis in PSP demonstrates characteristic abnormalities that distinguish it from other parkinsonian syndromes. Spectral analysis reveals a pattern of generalized slowing with increased theta and reduced alpha power, reflecting cortical dysfunction secondary to subcortical degeneration.
Key EEG findings in PSP:
| Finding |
Description |
Clinical Significance |
| Generalized slowing |
Increased theta (4-8 Hz) and reduced alpha (8-13 Hz) power |
Correlates with cognitive impairment severity |
| Diffuse background slowing |
Reduced beta (13-30 Hz) activity |
Indicates cortical network disruption |
| Frontal intermittent rhythmic delta activity (FIRDA) |
Burst of rhythmic delta waves |
Associated with subcortical and brainstem involvement |
| Sleep architecture disruption |
Reduced REM sleep, increased sleep fragmentation |
Reflects brainstem reticular formation involvement |
The EEG slowing pattern in PSP correlates with disease severity and cognitive impairment, providing an objective measure of cortical dysfunction that complements clinical rating scales.
Computerized EEG analysis provides sensitive metrics for tracking disease progression:
- Relative alpha power: Significantly reduced in PSP compared to healthy controls and PD
- Theta/alpha ratio: Elevated in PSP, correlating with frontal executive dysfunction
- Coherence analysis: Reduced interhemispheric coherence in frontal regions, indicating corpus callosal dysfunction
- Event-related spectral perturbations: Altered alpha suppression during cognitive tasks
EEG features can aid in differentiating PSP from other parkinsonian syndromes:
- PSP vs. Parkinson's Disease: PSP shows more pronounced generalized slowing and less prominent alpha reactivity
- PSP vs. Corticobasal Syndrome (CBS): CBS may show more focal asymmetry, while PSP shows more symmetric generalized slowing
- PSP vs. Multiple System Atrophy (MSA): Both show EEG slowing, but MSA may retain more alpha reactivity in early stages
Auditory ERP studies provide sensitive measures of cognitive processing in PSP. The N200 and P300 components are particularly informative.
N200 component:
- Represents early sensory processing and target discrimination
- PSP patients demonstrate prolonged N200 latency compared to healthy controls
- Reflects impaired auditory processing speed at the cortical level
P300 (P3b) component:
- Associated with attention and working memory processes
- PSP patients show significant P300 latency prolongation (mean delay ~50-80 ms vs. controls)
- P300 amplitude reduction indicates attentional resource limitation
- Prolonged P300 latency correlates with cognitive impairment severity on neuropsychological testing
A landmark comparative study demonstrated that PSP and CBD patients show different electrophysiologic features when examined with multimodal evoked potentials. PSP patients showed "significant prolongation of the N200 and P300 latencies of auditory event-related potentials compared with controls," and these findings distinguished the two diseases from each other (PMID: 9746295).
Visual ERPs in PSP reveal processing abnormalities at both early and late stages:
Pattern-reversal visual evoked potentials (PR-VEP):
- P100 latency may be normal or mildly prolonged in early PSP
- Significant P100 prolongation in advanced disease
- May reflect optic radiations or occipital cortex involvement
Face-processing ERPs (N170, N250, P300):
- Altered face-processing components in PSP patients with visual recognition deficits
- May correlate with the visuospatial dysfunction seen in PSP
SSEP studies reveal both peripheral and central somatosensory pathway involvement:
- Upper limb SSEP: Normal peripheral and spinal components; possible prolongation of cortical (N20-P30) responses
- Lower limb SSEP: More frequently abnormal, reflecting the caudally-progressing brainstem degeneration in PSP
- Cortical SSEP amplitudes: Reduced in PSP compared to PD, indicating cortical sensory processing deficit
TMS studies in PSP reveal complex patterns of cortical excitability changes that differ from those seen in Parkinson's disease:
Motor thresholds:
- Resting motor threshold (rMT): May be elevated in PSP, indicating reduced cortical excitability
- Active motor threshold (AMT): Variable findings across studies
Motor evoked potentials (MEP):
- MEP amplitudes may be reduced in PSP, reflecting corticospinal tract involvement
- Central motor conduction time (CMCT): Prolonged in PSP, consistent with upper motor neuron involvement
- CMCT prolongation correlates with disease duration and severity
SICI testing reveals distinct patterns in PSP that may differentiate it from other parkinsonian syndromes:
- Reduced SICI: Indicates cortical disinhibition, similar to findings in CBS
- PSP vs. PD: PSP shows more pronounced SICI reduction than PD
- Correlation with clinical features: SICI abnormalities correlate with axial rigidity and falls
| Paradigm |
Finding in PSP |
Interpretation |
| SICI (2-5 ms interstimulus interval) |
Reduced inhibition |
Cortical interneuron dysfunction |
| Intracortical facilitation (ICF, 7-20 ms) |
Normal or reduced |
Variable interneuronal involvement |
| Long-interval intracortical inhibition (LICI, 100-200 ms) |
Reduced |
GABA-B receptor dysfunction |
¶ TMS in Diagnosis and Prognosis
- Diagnostic utility: TMS parameters may help differentiate PSP from PD with 70-80% sensitivity
- Prognostic value: Baseline SICI reduction predicts faster progression to falls and wheelchair dependence
- Biomarker potential: TMS measures show sensitivity to disease progression over 12-24 month intervals
Cerebellar stimulation studies reveal cerebellar involvement in PSP:
- Cerebellar brain inhibition (CBI): Reduced in PSP, indicating dentate nucleus involvement
- Cerebellar-cortical connectivity: Abnormal cerebellar modulation of motor cortex activity
BAEP studies assess brainstem auditory pathway integrity, which is relevant given the significant brainstem degeneration in PSP:
| BAEP Component |
Generator |
Findings in PSP |
| Wave I |
Auditory nerve (distal) |
Usually normal |
| Wave II |
Cochlear nucleus |
Variable |
| Wave III |
Superior olivary complex |
May be prolonged in advanced PSP |
| Wave IV |
Lateral lemniscus |
Often abnormal |
| Wave V |
Inferior colliculus |
Prolonged latency; reduced amplitude |
| I-V interpeak interval |
Central conduction time |
Prolonged in ~30-40% of PSP patients |
BAEP abnormalities in PSP reflect the involvement of the pontomesencephalic tegmentum, which contains key auditory processing nuclei. The prolongation of central BAEP intervals (particularly III-V and I-V) indicates brainstem dysfunction that may be subclinical.
- Gait impairment severity: Patients with prolonged BAEP intervals show more severe postural instability
- Ocular motor dysfunction: BAEP abnormalities correlate with vertical saccade velocity reduction
- Disease duration: BAEP prolongation increases with longer disease duration
Pattern-reversal VEP studies in PSP provide information about visual pathway integrity:
- P100 latency: Usually normal in early PSP; may become prolonged in advanced disease
- P100 amplitude: May be reduced, particularly in patients with significant visual processing complaints
- N75 component: Often preserved, indicating peripheral visual pathway integrity
¶ Color Vision and VEP
- Patients with PSP who have color discrimination deficits show altered VEP responses to chromatic stimuli
- May reflect both pregeniculate (retina) and postgeniculate (visual cortex) involvement
Electrophysiological measures have been investigated as potential diagnostic biomarkers:
| Measure |
Sensitivity |
Specificity |
Notes |
| P300 latency > 380 ms |
~70% |
~80% |
Distinguishes PSP from PD |
| CMCT prolongation > 8 ms |
~60% |
~75% |
Reflects corticospinal involvement |
| BAEP III-V interval > 2.1 ms |
~40% |
~85% |
Specific for brainstem involvement |
| QEEG theta/alpha ratio > 1.5 |
~75% |
~70% |
Non-specific for PSP |
Longitudinal electrophysiological studies suggest these measures can track disease progression:
- P300 latency: Increases by ~10-15 ms per year in PSP
- EEG spectral changes: Progressive reduction in alpha power over 12-24 months
- MEP amplitudes: Decline correlates with clinical deterioration
Combining multiple electrophysiological measures may improve diagnostic and prognostic accuracy:
- A composite score incorporating P300 latency, CMCT, and theta/alpha ratio achieved AUROC of 0.85 for PSP vs. PD differential diagnosis
- Longitudinal changes in composite scores correlated with clinical progression rates
| Electrophysiological Measure |
PSP |
PD |
| P300 latency |
Prolonged |
Normal or mildly delayed |
| SICI |
Markedly reduced |
Mildly reduced |
| EEG alpha power |
Reduced |
Relatively preserved |
| CMCT |
Prolonged |
Usually normal |
- Both PSP and CBS show reduced SICI, but CBS may show more pronounced asymmetry
- MEP abnormalities more prominent in CBS
- P300 changes similar in both conditions
- EEG slowing more pronounced in PSP
- P300 abnormalities similar in both conditions
- MSA may show more prominent BAEP abnormalities in early stages
¶ Standardization Challenges
Electrophysiological testing in PSP faces several methodological challenges:
- Patient cooperation: Cognitive impairment and oculomotor dysfunction may limit complex ERP and TMS protocols
- Medication effects: Antiparkinsonian medications can affect some TMS parameters (L-dopa may normalize SICI)
- Age-matched controls: Essential for interpretation given age-related changes in many electrophysiological measures
For EEG:
- Minimum 20-minute resting EEG with eyes closed
- Quantitative analysis with spectral decomposition
- Hyperventilation and photic stimulation if patient can cooperate
For ERP:
- Auditory oddball paradigm (standard: 1000 Hz, target: 2000 Hz; 80/20 ratio)
- Minimum 40 artifact-free trials per condition
- P300 extracted from midline electrodes (Fz, Cz, Pz)
For TMS:
- Motor hotspot identification using neuronavigation where available
- Standard paired-pulse SICI/ICF protocols
- Record both upper and lower limb motor responses
Electrophysiology can be incorporated into the diagnostic evaluation of suspected PSP:
- Routine EEG: Helps exclude other causes of cognitive decline (epilepsy, metabolic encephalopathy)
- ERP testing: P300 latency prolongation supports PSP diagnosis in ambiguous cases
- TMS: CMCT prolongation and SICI reduction support diagnosis
Serial electrophysiological assessments can track disease progression:
- Baseline ERP and EEG: Establish disease-specific patterns
- 6-month reassessment: P300 latency changes correlate with clinical progression
- 12-month comprehensive assessment: Include motor threshold, SICI, and EEG
Electrophysiological measures may help assess treatment effects:
- L-dopa response: TMS parameters can document motor cortex excitability changes
- Neuroprotective trials: EEG and ERP may serve as non-invasive outcome measures
- High-density EEG (256+ channels): Improved spatial resolution for source localization
- TMS-EEG combined: Direct measurement of cortical excitability changes without motor response
- MEG (magnetoencephalography): Superior temporal resolution for studying brain oscillations
- Transcranial electrical stimulation (tES): Both therapeutic and diagnostic applications
Combining electrophysiology with other modalities:
- EEG-fMRI: Investigating brain network changes underlying EEG patterns
- TMS-EEG-PET: Correlating cortical excitability with neuroinflammation markers
- Evoked potentials with structural MRI: Correlating BAEP/ERP findings with brainstem and cortical atrophy
Advanced analysis of electrophysiological data:
- Support vector machines: Using P300 and EEG features for automated classification
- Deep learning: CNN-based analysis of raw EEG for PSP detection
- Multimodal fusion: Integrating EEG, ERP, and TMS features for improved accuracy
- Takeda M et al., Electrophysiologic comparison between corticobasal degeneration and progressive supranuclear palsy. Clin Neurol Neurosurg (1998) PMID: 9746295
- Stamelou M et al., Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord (2008) PMID: 18464278